Evidence map›Paper›PMID 41820390›Full record

ArticleScientific reports2026

Alkaloids from Evodia rutaecarpa inhibit the occurrence and development of gallbladder cancer in vivo and in vitro.

Yijie Li, Shufen Zhou, Hanzheng Xu, Hongye Zhou, Kunqi Sun, Siyang Hu, Ke Xu, Jiahua Yang, Yafeng Chen, Wei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yijie LiPutuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China.
Shufen ZhouState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Hanzheng XuState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Hongye ZhouState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Kunqi SunState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Siyang HuPutuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China.
Ke XuInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Jiahua YangPutuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China. yangjiahua7@163.com.
Yafeng ChenPutuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China. yafengchen9@hotmail.com.
Wei LiPutuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200333, China. liwei1511972@163.com.

Funding

Fujian Provincial Natural Science Foundation of China No. 2024J01222Science and Technology Innovation Project of Shanghai Putuo District Health and Wellness Plan No. ptkwws202308Shanghai Health System Key Disciplines - General Surgery No. 2024ZDXK0046the Clinical Specialized Disease Construction Project of Shanghai Putuo District Municipal Health Commission No.2024tszb01the National Key Research and Development Program of China No. 2024YFA1108604
6 · The paper itself

Abstract

Objective Gallbladder cancer (GBC) poses a significant health burden with dismal prognosis due to frequent metastasis and recurrence. Although evodiamine has demonstrated potent inhibitory effects on proliferation and metastasis in various cancers, its role in GBC remains unexplored, and the underlying mechanisms are yet to be elucidated.

methodsThe inhibitory effects of evodiamine on GBC cells were evaluated in vitro using a cell viability assay. Cell migration capacity was assessed via wound healing and Transwell assays. Apoptosis and cell cycle distribution were analyzed by flow cytometry and Western blotting (WB). The molecular mechanisms were investigated using Quantitative polymerase chain reaction (qPCR) and WB to quantify ZEB1 gene expression. In vivo, the anti-tumor activity of evodiamine was verified in a nude mouse model.

resultsEvodiamine significantly inhibited the proliferation of GBC cells. Flow cytometry and Western blotting revealed that evodiamine induced G2/M phase arrest and promoted apoptosis. mRNA-sequencing (mRNA-seq) demonstrated that evodiamine suppressed the transcription of ZEB1 and genes in the PI3K-Akt signaling pathway. Consistent with in vitro findings, evodiamine exhibited remarkable antitumor effects in a nude mouse model.

conclusionThis study confirms that evodiamine inhibits GBC cell proliferation and induces apoptosis. The mechanism involves suppression of ZEB1 expression and inactivation of the PI3K-Akt signaling pathway.

Indexed as

AlkaloidsEvodiaGallbladder NeoplasmsQuinazolinesAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHumansMiceMice, NudePhosphatidylinositol 3-KinasesSignal TransductionAlkaloidsevodiaminePhosphatidylinositol 3-KinasesQuinazolinesZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1EvodiamineGallbladder cancerProliferation, metastasisZEB1

Identifiers

PMID41820390
PMCPMC13106714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.